Abvance Therapeutics
David Maggs is currently the Chief Executive Officer at Abvance Therapeutics. David also serves as an Advisor and Consultant at 4MED Consulting LLC and as Adjunct Faculty at UT Health San Antonio. David's past experience includes roles such as Vice President at Becton Dickinson and Chief Medical Officer at Fractyl Labs and GI Dynamics. Maggs holds a degree in MBBS from Guys Hospital, University of London.
This person is not in any teams
This person is not in any offices
Abvance Therapeutics
Traditional insulin replacement therapy involves multiple daily insulin injections or the delivery of insulin by a pump, the need for careful blood glucose monitoring, and the fear of an unwanted fall in blood glucose (hypoglycemia). Fear of hypoglycemia prevents optimal glycemic management leading to long-term hyperglycemia and damage to the body (kidney, heart, extremities). Abvance is a biotechnology company developing a new insulin: glucagon formulation called ABV100 for preventing hypoglycemia. Patients who use ABV100 instead of insulin will experience improved blood glucose control with a safety buffer against hypoglycemia. In addition, ABV100 does not require new behavioral changes or devices and will lighten the daily burden of disease management. ABV100: A titratable, fixed ratio combination of two FDA-approved peptides to control glycemia while mitigating the threat of hypoglycemia.